Universität zu Köln

Journal Article

Roemer, Margaretha G. M., Redd, Robert A., Cader, Fathima Zumla, Pak, Christine J., Abdelrahman, Sara, Ouyang, Jing, Sasse, Stephanie, Younes, Anas, Fanale, Michelle, Santoro, Armando ORCID: 0000-0003-1709-9492, Zinzani, Pier Luigi, Timmerman, John, Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trneny, Marek, Ansell, Stephen, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Sumbul, Anne, Armand, Philippe, Neuberg, Donna S., Pinkus, Geraldine S., Ligon, Azra H., Rodig, Scott J. and Shipp, Margaret A. (2018). Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J. Clin. Oncol., 36 (10). S. 942 - 954. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Armand, Philippe, Engert, Andreas, Younes, Anas, Fanale, Michelle, Santoro, Armando ORCID: 0000-0003-1709-9492, Zinzani, Pier Luigi, Timmerman, John M., Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trneny, Marek, Shipp, Margaret A., Kato, Kazunobu, Sumbul, Anne, Farsaci, Benedetto ORCID: 0000-0001-8275-2561 and Ansell, Stephen M. (2018). Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J. Clin. Oncol., 36 (14). S. 1428 - 1450. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S. W., Felip, Enriqueta, Chow, Laura Q. M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey ORCID: 0000-0002-2603-7296, Santoro, Armando ORCID: 0000-0003-1709-9492, Sutradhar, Santosh, Li, Siyu, Szczudlo, Tomasz, Yovine, Alejandro and Shaw, Alice T. (2016). Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol., 17 (4). S. 452 - 464. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Younes, Anas, Santoro, Armando ORCID: 0000-0003-1709-9492, Shipp, Margaret, Zinzani, Pier Luigi, Timmerman, John M., Ansell, Stephen, Armand, Philippe, Fanale, Michelle, Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B., Collins, Graham ORCID: 0000-0002-8803-4234, Savage, Kerry J., Trneny, Marek ORCID: 0000-0002-6952-6073, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Parker, Susan M., Rodig, Scott, Roemer, Margaretha G. M., Ligon, Azra H. and Engert, Andreas (2016). Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol., 17 (9). S. 1283 - 1295. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Shaw, Alice, Mehra, Ranee, Tan, Daniel S. W., Felip, Enriqueta, Chow, Laura Q. M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey, Santoro, Armando ORCID: 0000-0003-1709-9492, Geraldes, Margarida, Sen, Paramita, Boral, Anthony J., Yovine, Alejandro and Kim, Dong-Wan (2014). CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK plus ) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL. Neuro-Oncology, 16. CARY: OXFORD UNIV PRESS INC. ISSN 1523-5866

Shaw, Alice T., Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S. W., Felip, Enriqueta, Chow, Laura Q. M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey ORCID: 0000-0002-2603-7296, Santoro, Armando ORCID: 0000-0003-1709-9492, Lau, Yvonne Y., Goldwasser, Meredith, Boral, Anthony L. and Engelman, Jeffrey A. (2014). Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer. N. Engl. J. Med., 370 (13). S. 1189 - 1198. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Tan, Daniel Shao-Weng, Shaw, Alice Tsang, Mehra, Ranee, Felip, Enriqueta, Chow, Laura Quan Man, Camidge, D. Ross, Vansteenkiste, Johan F., Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin H., Liu, Geoffrey, Santoro, Armando ORCID: 0000-0003-1709-9492, Geraides, Margarida, Boral, Anthony, Yovine, Alejandro Javier and Kim, Dong-Wan (2014). Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) NSCLC: Subgroup analysis of the ASCEND-1 trial. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel Shao-Weng, Felip, Enriqueta, Chow, Laura Quan Man, Camidge, D. Ross, Vansteenkiste, Johan F., Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin H., Liu, Geoffrey, Santoro, Armando ORCID: 0000-0003-1709-9492, Geraldes, Margarida, Boral, Anthony, Yovine, Alejandro Javier and Shaw, Alice Tsang (2014). Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial. J. Clin. Oncol., 32 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Faivre, Sandrine J., Santoro, Armando ORCID: 0000-0003-1709-9492, Kelley, Robin Kate, Merle, Philippe, Gane, Ed, Douillard, Jean-Yves, Waldschmidt, Dirk, Mulcahy, Mary Frances, Costentin, Charlotte, Minguez, Beatriz ORCID: 0000-0002-7276-9666, Papappicco, Pasqua, Gueorguieva, Ivelina, Cleverly, Ann, Desaiah, Durisala, Lahn, Michael M., Ameryckx, Sophie, Benhadji, Karim A., Raymond, Eric and Giannelli, Gianluigi (2014). A phase 2 study of a novel transforming growth factor-beta (TGF-beta 1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 32 (3). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755